Our Mission
NovaCodeBio's mission is to disrupt and accelerate transformative therapy discovery and delivery, establishing a global biotech powerhouse.
We leverage a revolutionary platform built on 35 years of peptide discovery expertise from the OBOC technology inventor and leader in combinatorial chemistry, combined with cutting-edge automation and AI.
NovaCode Bio is committed to defeating high-impact diseases through groundbreaking therapies that address urgent medical needs. Leveraging over 30 years of innovative research, our unique platform targets well-established disease pathways to deliver life-changing solutions with precision and speed.
Redefining Therapeutic Boundaries
80–90% of disease drivers remain unreachable.
Most CNS therapies never cross the blood–brain barrier.
Precision delivery remains a daunting challenge.
At NovaCode, we harness the unparalleled versatility of peptides—and beyond—to rewrite these limits. Powered by our unbiased discovery platform and precision nano-delivery system, we aim to transform what's possible in human medicine.
Company Snapshot
Our Team
KS Lam, MD, PhD
University of California Davis, California
- Distinguished Professor, Department of Biochemistry & Molecular Medicine
- Inventor, OBOC combinatorial chemistry
- 30 years of clinical experience to treat cancer patients
- Leader in nanomedicine, drug development and combinatorial chemistry research
Stephen Mason, PhD
- Twenty-five years of drug discovery and development experience on first-in-class small and large molecules
- Contributed to the discovery of nirmatrelvir, the anti-COVID-19 component of PAXLOVID
- Experience in both biotech and large pharma, such as Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and J&J
Shawn Mu, MBA, PhD
- Co-founder of 2 start-up companies in new drug development, including advanced drug delivery platforms and first-in-class small molecules
- Extensive experience in drug delivery and the generic drug industry, holding multiple patents in drug delivery technology
- Management experience at international pharma corporations such as Sanofi-Aventis and KV Pharma
Ruiwu Liu, PhD
Professional Researcher at UC Davis Cancer Center; Ph.D. in Medicinal Chemistry;
- Pioneered OBOC/OB2C combinatorial library methods for drug discovery,
- 100+ peer-reviewed articles (Nature Communications, JACS), 40+ on combinatorial chemistry,
- 6 patents, and 8 book chapters.
Contact Us
Shawn Mu: shawnmu02@yahoo.com
Steve Mason: steve.mason295@gmail.com
Focus on Innovation & Exploration
Innovation is at the heart of everything we do. Our journey of discovery is just beginning.